Product Description: Lucerastat (Standard) is the analytical standard of Lucerastat. This product is intended for research and analytical applications. Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Formula: C10H21NO4
References: [1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21./[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
CAS Number: 141206-42-0
Molecular Weight: 219.28
Research Area: Metabolic Disease
Target: Glucosylceramide Synthase (GCS);Reference Standards